Richardcyoung.com

The Online Home of Author and Investor, Dick Young

  • Home
  • How We Are Different
  • About Us
    • Foundation Principles
    • Contributors
  • Investing
    • You’ve Read The Last Issue of Intelligence Report, Now What?
  • Your Survival Guy
  • The Great Reset
  • COVID-19
  • My Rifles
  • Concentrate on Dividend Record and Compounding
  • Your Security
  • The Swiss Way
  • Dick Young
  • Debbie Young
  • Key West
  • Paris
  • Dick’s R&B Top 100
  • Liberty & Freedom Map
  • Your Health
  • Ron Paul
  • Bank Credit & Money
  • Freedom Force
  • Dick Young’s Safe America
  • Bank for International Settlements

Statin Drugs/NNT Alert

October 17, 2017 By Richard C. Young

Originally posted April 25, 2014.

If you have been prescribed a statin drug, you will benefit greatly by reading the research presented here, here and here. The concept of NNT, or number needed to treat, offers compelling insight for every patient regardless of the prescribed drug or disease in question.

The harms of statins are less publicized than benefits, but are well documented. A recent narrative review of statin myopathy suggests that 10% is a relatively conservative estimate for this side effect,1 which may be a primary contributor to high rates of drug discontinuation.2 An additional, more concerning side effect is statin-induced diabetes, as noted in the JUPITER study and a large Women’s Health Initiative cohort, studies that best represent primary prevention cohorts.3 We use an absolute risk estimate for statin-induced diabetes with the understanding that this may underestimate risk for many. Baseline risk of diabetes is likely the greatest driver of risk for statin-induced diabetes, and the JUPITER trial enrolled patients at lower risk (2.4%) than many, perhaps most, patients who take statins. Our calculation presumes this low baseline risk and that the aggregate chance of diabetes is time-dependent and linear. We have thus extrapolated from the 1.9-year trial data to a 5-year endpoint, the same time endpoint and calculation used for benefits. These data are relevant to new onset diabetes only, and do not address the equally concerning possibility that some diabetic patients may experience statin-induced worsening of their disease, or inability to manage or cure their disease using lifestyle changes. We look forward to data addressing these issues.

Our sense, based on factors noted above, is that the benefits of these drugs are likely exaggerated partly by an unconscious ‘hope bias’ on the part of readers and authors. This is common in the early literature on therapeutic innovations, and is often attenuated as further literature emerges. In addition, post-marketing surveillance data is in its early stages with this class of drugs and preliminary reports suggest that cognitive decline, tendonopathies, and other side effects may emerge in future literature. Finally, the source of the great majority of these data is industry, which has a spotty history of integrity in trial data reporting, suggesting these data to be a best-case scenario.

Related video:

Related Posts

  • Statin Drugs: Part 1
  • Statin Drugs: Part 2
  • Statin Drugs: Part 3
  • Author
  • Recent Posts
Richard C. Young
Richard C. Young is the editor of Young's World Money Forecast, and a contributing editor to both Richardcyoung.com and Youngresearch.com.
Latest posts by Richard C. Young (see all)
  • Neither Cancel Culture nor COVID Can Shut Down CPAC - February 26, 2021
  • Has Bill Gates Been Injected Yet? - February 26, 2021
  • Fauci Doesn’t Own Your Face - February 25, 2021

Dick Young’s Must Reads

  • Why Black Lives Matter Needs to Be Shut Down
  • You Can’t Help But See the Truth About the Soviet Union in Chernobyl
  • Yes! Money Can Bring You Happiness
  • Boom—Your Life Changes
  • A Look at the Future of Main Street America
  • Blue Dog Democrats Must Stop the Squad’s Assault on America
  • Democracy: The Most Dangerous and Insidious Effect of Majority Rule.
  • The Armed American Family: Part I
  • America’s States Rights Revolution
  • Hungarian Hardliner Viktor Orban Shows European Globalists the Way

Disclosure

RSS Youngresearch.com

  • Welcome to the Interest Rate Prediction Business, JACK!
  • Democrats Have a Plan: Don’t Get Too Attached to Your Capital Gains
  • Petrified Snow/Ice Fishing? How about a Boat? and More
  • Bubble in Tech Stocks Will Cause “Clean Out” in Markets
  • COVID Chaos: New York and California vs. Florida and South Dakota
  • Time for the Fed To Stop Babying the Bond Market
  • Richard Young Reports: 50+ Years with Fidelity and Wellington
  • Deep Survival, Who Lives, Who Dies, and Why
  • Herd Immunity by April?
  • Corporate Bond Yields: What You Can Earn Today

Neither Cancel Culture nor COVID Can Shut Down CPAC

The Political Downside of Stoking Fear

Welcome to the Interest Rate Prediction Business, JACK!

Has Bill Gates Been Injected Yet?

Fauci Doesn’t Own Your Face

Gov. Newsom Discovering the Power of the Pen

Copyright © 2021 | Terms & Conditions | About Us | Dick Young | Archives